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jEditorial
Considerations of Risks Versus Benefits
by Hans L. FaIk
An evaluation of risks versus benefits from new products should be encouraged, even
when dealing with agents which may cause cancer or malformations in laboratory
animals, because there is evidence that safety thresholds exist even for such exposures.
However, it is not easy to describe risk and benefit in comparable terms when they
may involve generations to come and events in the future.
Risk versus benefit analysis regarding the
exposure of man and his environment to new
chemical, physical, or. biological agents result-
ing from altered or new technological develop-
ments, has become a familiar phrase. It has been
on the minds of scientists, public health officials
or administrators, but has not resulted in tech-
nical or conceptual clarification regarding the
requirements for satisfactory analysis. Dif-
ferent points of view on benefits to society
and on willingness to take calculated risks can
be heard. Individuals may be willing to take
risks and enjoy the realization of having taken
risks-in driving cars, flying planes, participat-
ing in certain sports, or by sticking to their pack
of cigarettes a day.
Taking risks with the health of the unsuspect-
ing public, however, is quite a different matter.
The risks we shall deal with here are of the
latter type, and it is up to those entrusted with
safeguarding the public health to make risk/
benefit evaluations for society and the environ-
ment on the basis of information available to
them. Usually such information on potential
hazards of newly developed products or sub-
stances is fragmentary and woefully inadequate.
It is not only a matter of research funds or
time until "complete safety evaluations" will be
forthcoming but a profound question of how far
such safety determinations can be attempted
even with all the ingenuity of science at its
disposal.
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Although it may appear as if two camps
with closed lines regarding benefits or risks
were confronting each other, this is not true.
Experts on risks to man and his environment
bring different arguments to the debate than
do experts on benefits except in the area of
drug development. Here risks and benefits focus
on the same individual and he is often willing
to take great risks where the alternative is
the certainty of ill health or death. Under these
conditions, risks to society as a whole are
subjugated to considerations of the individual.
Alternatives
Some agreement has been seen in the evalua-
tion of costs versus benefits for certain develop-
ments where, for instance, the dollar cost for
installation of air cleaning equipment could be
equated with the value of reduction of toxic
components in the air. This was then compared
to lower frequency of respiratory infections,
improved visibility, or reduced deterioration of
consumer products. A case was made for the
replacement of the cheap pesticide DDT by a
more expensive one which also required more
frequent application and proved very hazardous
in the field to man and beast. Other hoped-for
developments in insect control focus on
chemosterilants, which may also carry a
definite risk. This, however, is reduced by com-
bining them with specific insect sex attractants,
thus avoiding at least elimination of harmless
or beneficial insects. Other alternatives, like
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bacteria or viruses for insect control have been
developed. The greatest promise for a satisfac-
tory solution has recently come from develop-
ment of interference with reproduction by
alteration of the proportion of isomers of sex
attractants, leading to a no-risk situation except
for those natural predators that will find their
food supply depleted. With such developments
around the corner the use of DDT may decline
in spite of the tremendous service that the
chemical has given man in disease control, but
even for those situations, development of resist-
ance in the insects serving as disease vectors
has required the use of alternative pesticides
until resistance in the species has declined.
Although these evaluations of the costs of
changes in agricultural or public health prac-
tices can give us useful information, the risk
of building up DDT in human adipose tissue to
much higher levels has not so far been
evaluated.
Benefits
In situations where risks to man or the en-
vironment may not exist, there may still be
disagreement regarding the benefits to society.
Rain or snow cloud seeding has been considered
a low-risk task, but the practice has raised ques-
tions regarding the rights to clouds. Aided
precipitation may deprive a neighboring area
from getting its accustomed supply of rain.
Alternatively, cloud seeding may serve a local
farming population but not those that depend
on tourist trade. These may not be real problems
but benefit evaluation will have to take many
subgroups of the population into consideration.
Announcements of benefits to be derived from
new chemical developments often stress the
value to the consumer: e.g., the availability of
cheaper or better or more durable products;
the contribution to improved health of the
general population; better utilization of re-
sources; or greater productivity of industry,
greater employment of the work force or even
improved balance of trade for the country. All
these points are successfully documented.
Risks
To consider the risks, experts in different
fields may want to be heard. The environ-
mentalists will focus on damage to the en-
vironment, including the decline ofmany species
most people hardly know by name, or on excess
use or misuse of natural resources. The toxi-
cologists may worry about acute toxicity,
delayed toxicity, or may be concerned about the
impact on the food chain and cumulative
toxicity in order to determine the hazards to
man. Except in situations of acute toxicity
ending in death, an assessment of the dollar
value of the risk is not usually attempted, be-
cause costs of morbidity or unhappiness with
environmental changes (such as loss of beauty)
are nearly impossible to assess. However, there
is great merit in such dialogues on risks versus
benefits when arguments are presented with
utter conviction and sincerity on both sides.
When a conclusive evaluation of the risk
still seems impossible, the temporary solution
to the problem may lie in a carefully planned
limitation of use of the product, with proper
education in the handling of the material and
attention to the correct means of disposal of the
chemical. There might be information on the
time span until a better product can be de-
veloped. This would appear preferable to taking
no action until all the pieces on risk fit together
or until a new product is developed for which
a cleaner bill of health may be given. This
may be misleading because, for reasons of its
newness, fewer studies on potential risks will
have been made.
Extrapolation to the Human Situation
An evaluation of the risk for man has even
been difficult where epidemiological data could
point a finger at a specific environmental or
occupation exposure because it might have been
impossible to confirm a cause-and-effect rela-
tionship from animal experiments. Differences
in responses to exposure to toxic chemicals
between man and laboratory animals have often
been recorded and serve as warning that, in
the evaluation of the risks from new chemicals,
care has to be taken to plan experiments that
may be useful for extrapolation of the data to
man. Even so, some adverse health effects will
still only be detected on human exposure-
idiosyncrasies-but without too much risk for
the general population. Animal experimentation
can focus on serious health effects. Neverthe-
less, ototoxic effects, for instance, may be quite
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normal bioassay procedures.
When it is not possible to study health effects
on man during the development of new chemical
products and when animal experiments will
not give all the information needed, it is im-
portant to be aware of this grey area for which
no safety evaluation will be forthcoming. Few
experiments have been carried out on exposure
to stress, although stress has been studied to-
gether with exposure to environmental insults
as affecting the health of the unborn, i.e., where
abortions or malformations have been observed
in animal studies. The effects of stress have been
studied in many different situations, but no
laboratory experiments have been carried out
with the human suppressed reaction to stress,
which has been shown to lead to many types
of psychosomatic diseases (1). These conditions
will not be mimicked in animal experiments,
and allowance will have to be made for such
commonly encountered situations superimposed
on exposure to environmental toxicants.
Routine risk evaluation of a new chemical
starts easily enough with an evaluation of
chemical and physical data of relevance to
potential hazards: e.g., volatility, water or
lipid solubility, stability in the environment, or
degradability by chemical or biological means.
This information is supplemented with data on
acute toxicity, subacute toxicity, and informa-
tion on the reversibility of the adverse effects.
Helpful information is sometimes obtained from
a comparison of toxicity data from chemically
closely related compounds. This evaluation by
analogy, however, may go too far if it shows
a lack of hazard or recommends a ban of the
compound.
Chronic toxicity evaluation frequently cannot
be based on acute toxicity data. Inert lipid-
soluble compounds tend to accumulate in certain
tissues and may exert delayed toxicity which
would not be anticipated. Acutely toxic and
reactive compounds may have a no-adverse-
effect level at which, under continued exposure,
toxicity may manifest itself by symptoms quite
different from the symptoms of acute toxicity.
For carcinogenesis, such observations have fre-
quently been made.
Careless attempts to mimic conditions of
human exposure in animals may lead to un-
expected mistakes, because conditions may
not have been equivalent. Thus inhalation
of an aerosol in mice may give different deposi-
tion patterns and results than inhalation of the
aerosol in man. Feeding a lipid-soluble chemical
with the normal rodent diet may produce less
absorption of the chemical than would occur
with the usual human diet. By necessity, the
greatest discrepancy, however, is the difference
in dose required to produce a toxicologic effect
in the limited number of exposed animals
compared to the human population at risk.
Besides such anatomical differences of the
tracheobronchial tree or the differences in diet,
emphasis must be put on comparability of
absorption, distribution in the organism, reten-
tion and elimination of the chemical to obtain
the greatest degree of analogy in the risk
evaluation, and possible explanations of species
differences in observed response. Most critical
is the comparability of metabolism of the com-
pound which must be studied regarding all
major or minor pathways, metabolic shunts, and
the effects of administration of enzyme in-
ducers (intercurrent exposures to pesticides,
drugs, or food additives that may affect the
enzymatic pathways). Close control of the
animal colony regarding these factors may not
allow any extrapolation to man, who may have
developed preferential metabolic pathways due
to exposure to some enzyme inducer or inhibitor.
Carbon monoxide may serve as an example of
an inhibitor. A detailed study of human as well
as laboratory animal habits is quite essential.
The above points must be taken into con-
sideration in the planning stage or at least in
the evaluation of results. However, a very
difficult problem lies in the determination of
significance of negative findings, i.e., the extra-
polation to a safe dose. Already in 1954, Barnes
and Denz (2) grappled with this problem,
determining the minimum number of animals
required to control the risk of failing to observe
an adverse effect. To detect with a degree of
probability of 0.01 an adverse reaction occur-
ring in 1% of the animals, one would require a
group of no less than 455 animals. This re-
quirement has hardly been followed for the
reason that the cost of experiments would
become prohibitive, particularly for studies
of carcinogensis because of their long duration.
Exposure to still lower dosage to reach the level
of human exposure becomes unmanageable and
costly and still will not yield data that would
give any assurance of the safety of this ex-
posure for the total population.
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effect level" in animal experiments by extra-
polation have been discussed repeatedly.
Bliss (3) stated that the effect of low doses was
qualitatively different from that of high doses.
This problem has presented real difficulties
regarding the acceptance of no-adverse-effect
levels for carcinogenic chemicals when concepts
borrowed from radiation carcinogenesis were
transposed. These suggest that a single molecule
might cause a permanent change which might,
together with many similar events acting
cumulatively over a lifetime, produce cancer.
That this is not quite so could be shown by
exposing animals to low doses of a carcinogen
and allowing several months time before sub-
sequent treatments with a promoter of carcino-
genesis. When the carcinogenic response was
no longer as expected, it was suggested that
during the time interval many of the initiated
cells had disappeared or could no longer
respond (4).
Studying the events in carcinogenesis and
mutagenesis goes further to prove that the
reaction of carcinogens or mutagens with DNA
are not irreversible events. They need not lead
to the expression of mutations or cancer. Re-
pair of genetic damage has been established for
several species, from bacterial to human cells.
Evidence came from studies on bacterial super-
sensitivity to radiation, the induction of
mutator genes in bacteria (5) and from ob-
servations on patients with xeroderma pig-
mentosum (6) where sensitivity to sunlight
resulted in skin cancers in exposed areas. These
multiple cancers are due to inadequacy of the
cellular DNA repair mechanisms. Such defici-
encies can be induced by mutations or by ex-
posure to a few chemicals which interfere with
enzymatic activity (7) but these studies
surely demonstrate that in the general popula-
tion the irreversibility of a one-molecule event
at the DNA level does not apply, and therefore
that no-effect-thresholds must exist. It is true,
of course, that exposure to chemicals that can
block DNA repair mechanisms could present
an extreme health hazard and must be effec-
tively guarded against.
It should be realized that the heterogeneity
of the human population and their health ex-
periences during a lifetime present different
circumstances for which the findings of toxicity
in inbred strains of rodents or even random-
bred animals do not allow reliable extrapolation.
Genetic factors, as well as immunological,
nutritional, enzymatic alterations and many
other changes resulting from past or present
injury to organs or tissues may contribute their
share to enhance susceptibility to toxic agents.
For many of these conditions, the persons thus
afflicted are adequately prepared by knowing
about their increased vulnerability and by at-
tempting to protect themselves as long as the
harmful exposure can be identified.
For newly developed chemicals, toxicity data
will not necessarily alert the more susceptible
groups of the increased risk. The tests do
not even cover all potential adverse effects.
The hope that adverse effects-such as allergic
reactions-which are not evaluated by labora-
tory bioassay could be readily detected in man
may be fulfilled, while the adverse effects
relating to genetic or somatic debilities may
not be detected as readily or before harm may
become irreversible.
Interactions of environmental agents may
have a qualitively or quantitively different ad-
verse effect on man than each of the agents
separately. For many chemicals the encounter
need not be simultaneous, but even a time
interval of several days may still allow such
interactions. Some of these are of an antago-
nistic nature (8); many others are synergistic
(9). From our point of view these synergistic
interactions may be troublesome for the evalua-
tion of environmental risks.
A familiar example of synergism can be taken
from the field of flavors. It is well known that
flavors change in quality on addition of common
salt, but more so by addition of monosodium
glutamate or the disodium salts of 5'-inosinic
or 5'-guanylic acids or by maltol (10). A dif-
ferent kind of synergism is encountered by
cigarette smokers where the chemicals respon-
sible for the enhanced risk, particularly to lung
cancer, have not been identified but where good
evidence for synergism exists (11). In occupa-
tional cancer, synergism between carcinogenic
polycyclic hydrocarbons and other components
of crude oil has also been postulated to exist.
The effect of microsomal enzyme induction by
environmental chemicals or drugs in altering
the effectiveness or toxicity of drugs or chemi-
cals has been studied in depth. However be-
cause of differences in rates of induction of
several enzyme systems, some of them leading
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to predict whether toxicity of a chemical will
be reduced or enhanced, even if its metabolism
is well studied and the active compound identi-
fied. For instance, metabolism by ring hydro-
xylation versus N-hydroxylation can be men-
tioned, with the former leading to innocuous
products and the latter to potential carcino-
gens (8).
Synergism requires a certain concentration
of the interacting components. In the field of
carcinogenesis, when the promoter is present
at too low a concentration no synergism is
observed. However it is unfortunately not true
that high enough concentrations of promoters
are never encountered except under laboratory
conditions-witness all those, for instance, for
whom moderate smoking is not feasible.
Medical progress brings with it new proce-
dures such as the use of immunosuppression,
which has already produced an increased cancer
risk in the recipients (12). Similarly, lengthen-
ing the life expectancy of man will probably
result in an increased cancer risk, particularly
when by synergistic action the latent period of
cancer development will be shortened. Thus the
aging population will have to look forward to a
higher incidence of cancer as part of the price
of longevity.
REFERENCES
1. Levi, L., Ed. Society, Stress and Disease. The
Psychosocial Environment and Psychosomatic Dis-
eases. (Proceedings of an International Interdis-
ciplinary Symposium, Stockholm, 1970), Oxford
Univ. Press, London, 1971.
2. Barnes, J. M., and Denz, F. A. Experimental
methods used in determining chronic toxicity, a
critical review. Pharm. Rev. 6: 191 (1954).
3. Bliss, C. I. The calculation of the dose-mortality
curves. Ann. Appl. Biol. 22: 134, 307 (1935).
4. Roe, F. J. C., et al. On the persistence of tumor
initiation and the acceleration of tumour progres-
sion in mouse skin tumorigenesis. Int. J. Cancer
9: 264 (1972).
5. Morgan, K., Hastings, P. J., and von Borstel, R. C.
A potential hazard: Explosive production of muta-
tions by irduction of mutators. Environ. Health
Perspec. 1: 207 (1973).
6. Cleaver. J. E., Defective repair replication of DNA
in xeroderma pigmentosum. Nature 218: 652 (1968).
7. Witkin, E. M., Modification of mutagenesis initi-
ated by ultraviolet light through post-treatment of
bacteria with basic dyes. J. Cell Comp. Physiol.
58: (Suppl. 1): 135 (1961).
8. Falk, H. L. Anticarcinogenesis-an alternative. In:
Progress in Experimental Tumor Research-Inhibi-
tion of Carcinogenesis, Vol. 14. S. Karger, Basel,
1971, p. 105.
9. Falk, H. L., Chemical carcinogens, mutagens and
teratogens. In: Environmental Problems in Medi-
cine, W. D. McKee, Ed., Charles C Thomas, Spring-
field, Ill., 1974, Chap. 8.
10. Furia, T. E., and Bellanca, N., Eds., Fenaroli's
Handbook of Flavor Ingredients, Chemical Rubber
Co., Cleveland, Ohio, 1971.
11. Selikoff, I. C., Hammond, E. C., and Ching, J.
Asbestos exposure, smoking and neoplasia. J. Am.
Med. Assoc. 204: 106 (1968).
12. Fahey, J. L. Cancer in the immunosuppressed
patient. Ann. Inter. Med. 75: 310 (1971).
June 1975 5